From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|August 24, 2022
Daily Medication Pearl: Dextromethorphan and Bupropion (Auvelity)
Author(s)Saro Arakelians, PharmD
Auvelity is a combination of dextromethorphan and bupropion indicated for the treatment of major depressive disorder in adults.
Advertisement
Medication Pearl of the Day: Dextromethorphan and Bupropion (Auvelity)
Indication: Auvelity is a combination of dextromethorphan, an uncompetitive N-methyl D-aspartate (NDMA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults.
Insight:
- Dosing: Starting dose is 1 tablet once daily in the morning. After 3 days, increase to the maximum recommended dosage of 1 tablet twice daily, separated by at least 8 hours. Do not exceed 2 doses within the same day.
- Dosage forms: Extended-release tablets 45 mg/105 mg dextromethorphan/bupropion.
- Adverse events: Most common adverse reactions (≥5% and more than twice as frequently as placebo) are dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis.
- Mechanism of action: Dextromethorphan is an uncompetitive antagonist of the NMDA receptor (an ionotropic glutamate receptor) and a sigma-1 receptor agonist. The mechanism of dextromethorphan in the treatment of MDD is unclear. The mechanism of action of bupropion in the treatment of MDD is unclear; however, it may be related to noradrenergic and/or dopaminergic mechanisms. Bupropion increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.
Reference:
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5